Drug · Small Molecule

Lenvatinib

CI-DRUG-00000336Explore in graph →NCIt C95124 CHEMBL1289601 CIViC Approved

Regulatory

Approvals (25)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory25 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as LENVIMA (DIN 02484129) under ATC L01EX08 LENVATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Oct 21, 2019	health-canada-dpd
CA Health Canada	—	Marketed in Canada as LENVIMA (DIN 02484056) under ATC L01EX08 LENVATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Oct 21, 2019	health-canada-dpd
CA Health Canada	—	Marketed in Canada as LENVIMA (DIN 02468239) under ATC L01EX08 LENVATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 8, 2018	health-canada-dpd

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 2 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	168	78	58	369	25	CA, EU, US	Feb 13, 2015	2005-07
Malignant Liver Neoplasm	Approved	Phase 4	65	36	29	134	1	US	Feb 13, 2015	Jul 24, 2009
Malignant Kidney Neoplasm	Approved	Phase 4	16	6	6	31	3	EU, US	Feb 13, 2015	Aug 5, 2010
Malignant Uterine Corpus Neoplasm	Approved	Phase 3	7	3	1	11

Curated evidence

Clinical evidence (4)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–4 of 4 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
High1
Ipilimumab + Lenvatinib

Clinical trials

Trials with this intervention (388)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 388 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05007106	MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)	completed	Phase 2	611	Merck Sharp & Dohme LLCINDUSTRY	15	Sep 28, 2026	clinicaltrials
NCT06110793	A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer	active not recruiting

Molecule

Record

Kind: Small Molecule
Mechanism: Vascular endothelial growth factor receptor inhibitor
Targets: 3 genes
UNII: EE083865G2
Aliases: 6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]- 7-methoxy-, E 7080, E-7080, E7080, ER-203492-00, Kisplyx, Lenvatinib, Lenvatinib Mesylate, LENVIMA, Multi-Kinase Inhibitor E7080

Data updated 21 hours agoSource updated unknown

Identifiers

Codes (21)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01EX08	LENVATINIB
ATC (WHO)	L01XE	Antineoplastic agents
ATC (WHO)